CRN HIGHLIGHTS SAVINGS FROM SUPPLEMENTS USE

The CRN Foundation’s Supplement to Savings report identified up to US$17.7bn in annual net savings between 2022-30 from the use of specific dietary supplements by at-risk target populations most susceptible to coronary artery disease (CAD). Throughout February, American Heart Month, CRN will amplify the potential of dietary supplements to reduce the health impacts and healthcare costs of CAD. The chapters on CAD focus on four supplement regimens: 

  • Average annual cost savings from the widespread daily use of preventative amounts of omega-3 fatty acids EPA+DHA could be US$4.47bn 
  • Regular use of magnesium by specific at-risk populations amounts to average healthcare cost savings of US$2.32bn per year 
  • Regular use of vitamin K2 by specific populations could generate estimated annual cost savings of US$9.48bn 
  • The average cost savings from increased utilisation of soluble fibre for heart-health effects is US$1.47bn per year 

Nicholas Hall Writes: We talk a lot about the ability of the CHC industry to reduce the overall cost of public health as well as improving access, but it’s always good to see hard figures with which we can agree or disagree. Even if these estimates are too high – which I’m not saying is the case – a saving of up to US$18bn from coronary artery disease alone, and an even more important saving of lives, are to be greatly desired. To quote Steve Mister, the CRN’s President & CEO: “Today, most of our healthcare resources are spent after people are already afflicted with an ailment. We hope the broader medical community will take notice and evaluate how supplements can enhance nutrition and improve the overall health of their patients.”

I like Steve Mister’s terrier-like defence of dietary supplements, which we witnessed a second time this week when he (rightly) criticised the FDA for its unwillingness to take responsibility for regulating CBD. It is one thing to say that existing regulations cannot provide a pathway for CBD, although one wonders why it took four years to reach this conclusion, but where then is the pathway? Unless the FDA takes hold of this emerging category, it will continue to display all the characteristics of the Wild West, when we are seeking to avoid a “Gunflight at the CBD Corral”. And until firm but fair regulations are put in place, we are unlikely to attract major consumer players to this sector.

Monitor the latest launches across VMS with our dedicated innovation benchmarking tool, CHC New Products Tracker, which features almost 40,000 launches, all graded with a star rating. Subcategories such as CBD, eye health, omega-3 and various herbal supplements are tracked, plus many others. To find out more, or to set up a demo, please contact david.redford@NicholasHall.com.

H&B REPORT: WOMEN’S HEALTH A TOP WELLNESS TREND IN 2023

According to Holland & Barrett’s (LetterOne) Wellness Trends Report 2023, areas of particular interest to consumers this year will include:

  • Women’s wellness – a big business in 2022 – will ramp up even further, with personalised solutions and FemTech founders continuing to help lead the revolution on breaking down taboos around menopause, menstrual health, fertility and more
  • Wellness tech gets personal. From patches tracking dietary biomarkers to carbon levels in the breath determining metabolic function, the future is all about using health data for optimum health. Health tech innovation is also becoming more focused on key target groups, such as those suffering from, or at risk of, chronic conditions
  • Sleep As well as vitamin D and magnesium, newly-trending ingredients include glycine, spearmint and plant polyphenols, EGCG and l-theanine. Meanwhile, consumers are keeping orthosomnia — the worry about getting enough sleep — at bay with remedies containing lavender, chamomile and CBD. There will also be an increase in smart tech to synchronise circadian routines
  • Ayurveda Ayurvedic remedies such as ashwagandha and curcumin, combined with scientific scrutiny, are experiencing a rise in popularity 
  • Beauty from within Collagen’s status as a skin-smoothing beauty superhero is here to stay, but people are also starting to understand the broader benefits, and younger customers are using type 2 collagen supplements to keep their joints in optimal health
To read the full report, click here

Nicholas Hall Writes: Last Wednesday we held the NHC Start of the Year Meeting at our Southend-on-Sea HQ. What a pleasure after three years to have 35 team members in the room and most of the rest of our global team dialing-in. One of our main objectives was to brainstorm a new Strategic Narrative for the CHC industry, which will drive our Global Trends roadshow after the new DB6 data is published in early April. And, of course, the Strategic Narrative will be at the heart of New Paradigms for CHC 2023, which we have just scoped and which will be published in July. As usual I will write almost every word of this completely revised 4th edition, supported by what I truly believe to be the biggest and best market analysis and creative solutions team in the CHC industry – 54 out of our total headcount of 65 plus numerous network partners, associates and freelancers.

And many of the overarching issues to be discussed in New Paradigms are illustrated in the latest edition of CHC.Newsflash: women’s health, MedTech and FemTech, lifestyle products, natural remedies, sustainability and China (reviewed at a time when Dr Nouriel Roubini warns us in his latest book, Megathreats, of the dangers of deglobalisation). And even before we publish the new report, I hope to meet as many of you as possible at our April conference in London, when we will give you a sneak peek of the new Strategic Narrative.

I will be joined on stage in London by speakers from PAGB, Haleon and Perrigo, plus other industry experts, for our 33rd European CHC Conference 19-21 April. Exploring The Future Resumed, you can review the full agenda or explore group booking options by contacting elizabeth.bernos@NicholasHall.com.

STATINS COULD BE A NEW OPTION FOR MILLIONS

ENGLAND: Draft updated guidance from NICE recommends that the risk threshold at which statins should be offered to prevent cardiovascular events can now also be considered for people at a lower threshold, meaning that around 15mn more individuals could be eligible. Until now, people with a >10% risk over 10 years of a cardiovascular event should be offered a statin. However, an independent committee considered new evidence on their side-effects and safety. 

While statins can cause muscle pains, the best evidence shows that most people do not experience this and many more will get muscle pains whether they take statins or not than have muscle pain caused by statins. While the draft guidance continues to recommend that risk factors which can be addressed should be managed, including stopping smoking, reducing alcohol consumption, taking exercise and eating a healthy diet, atorvastatin 20mg can now be considered as part of shared decision-making for people with a <10% risk over 10 years of a first heart attack or stroke.

For a short while (2004-2010), the world’s only OTC statin, Zocor Heart-Pro (J&J, UK)

Nicholas Hall Writes: Last week I wrote about macro factors that might influence consumer health markets in the near future. Healthcare in general will experience both mega-threats and opportunities: a threat in the sense that inadequate provision of hospitals and general practitioners is likely to erode standards of public health, with serious political and economic consequences; but that in a more localised sense there is a huge opportunity for OTC players to promote the concept of self-care to a demographically-unbalanced population which increasingly will have to take better care of its own health.

Our lead story this week tracks the move towards even more statin prescriptions in the UK. Could this benefit CHC, bearing in mind that the low-dose statin Zocor Heart-Pro is a failed switch from the past? Yes, I believe there is room for optimism, not least because renewed consumer interest in cardiovascular health could drive demand for an OTC polypill containing a statin and other beneficial ingredients such as omega-3 and possibly low-dose aspirin. Regulators stamped down on earlier attempts to create a polypill, but a generation later – and with declining standards of public health – who can say for sure that a revived interest in this concept would necessarily fail?

Explore innovation by marketer, region and country in the 2023 edition of our Innovation in CHC report, coming soon! Drawn from CHC New Products Tracker, this report showcases 10 major ingredient trends, 5 delivery format trends and 100 key innovations from 2022. For more information, or to pre-order your copy with the pre-publication discount, please contact melissa.lee@NicholasHall.com.

Stark 2023 growth warning from IMF head

The Managing Director of the International Monetary Fund has cautioned that 2023 is going to be a “tough year”, with one-third of the world economy expected to be in recession. The three big economies, USA, EU and China, are slowing simultaneously, translating to negative trends globally. Kristalina Georgieva added in an interview with the CBS News programme Face the Nation that, while USA is most resilient and may avoid recession, the strong labour market is a “mixed blessing” as interest rates could remain tight to lower inflation.

Meanwhile, half of the EU – severely hit by the war in Ukraine – will be in recession this year and China, which in 2022 slowed dramatically because of its zero Covid policy, will slow down further (+4.4% growth in 2023 projected) as the relaxation of restrictions leads to soaring coronavirus cases. Overall, IMF forecasts that Advanced Economies will grow by 1.1% in 2023, while Emerging Market and Developing Economies will rise by 3.7%, led by India (+6.1%) but dragged down by Russia (-2.3%).

When asked what leaves her hopeful, Georgieva said: “I know when we work together, we can overcome the most dramatic challenges. In 2020, the world came together in the face of tremendous threat and was able to overcome this threat. In 2023, we have to do the same.” 

Nicholas Hall Writes: For most of 2022 I wrote in CHC.Newsflash about a market performing surprisingly well, but there was an implicit warning that the party would come to an end one day. Kristalina Georgieva, head of the IMF, has issued a stark warning of tough times ahead economically, but that is light reading compared with Nouriel Roubini’s new book, “Megathreats”, which highlights the 10 trends that imperil our future. Known by some as Dr Doom, Roubini prefers to be known as Dr Realistic, but in my estimation he is Dr Right as he called out many past mistakes with great foresight, including the debt binge that has made the global economy today almost unmanageable.

So how will these megathreats affect Consumer Health? In one sense, we are privileged as healthcare is a must-have category, and self-care will fill part of the vacuum left by the inability of healthcare providers to meet the needs of a growing and demographically-unbalanced population, about which Dr Roubini also writes persuasively. But consumers can only spend the money in their pockets, regardless of whether it is earned or borrowed, which is why I am so concerned about the future of CHC brands and why generics and private labels are now seen as the new growth segment.

I’m also concerned about the viability of retailers and even e-Commerce platforms, as the economic crisis will lower customer footfall and push up costs including the cost of borrowing, forcing thousands of outlets to close. We are already seeing that as a sub-plot of today’s global medicine shortages. Partly this is a story of unpredictable demand caused by the afterwave of the Covid-19 pandemic, but it also seems to me that the supply chain has become very fragile as companies look for ways to cut costs by reducing inventory to breaking point. So our 2023 mission here at the Nicholas Hall Group is to reassess the Strategic Narrative for Consumer Health and offer advice to clients and the industry at large on how to survive mega- and microthreats.

We are pleased to announce that experts from Haleon, Perrigo and PAGB, plus our sponsors Pharmalinea will take the stage alongside Nicholas at our 33rd European CHC Conference! See the all-new agenda here. Taking place in London on 19-21 April 2023, save with the early bird booking discount when you book your place before 19 January! For more information, or for group booking discounts and sponsorship opportunities, please contact elizabeth.bernos@NicholasHall.com.

Relaxation of China Covid rules shakes up CHC market

The news that China is to ease its strict Covid-19 controls has had reverberations across Asia’s CHC market. From now onwards, individuals who have the virus can isolate at home instead of in state facilities; people will be able to travel more freely; and national apps to track people’s movements will be deactivated. Immediate reactions include the following:

  • JD Health has introduced an online Covid clinic offering 24/7 consultations for people with concerns about the virus; in the week following the easing of restrictions, the e-Commerce platform reported that sales of medicines for cold, fever and cough, as well as antibacterial and anti-inflammatory products, rose 18-fold vs the same period in October, and the transaction volume of antigen self-test kits increased by 344% week-on-week
  • High demand for analgesics and cold remedies in China has caused concerns about supply issues in S Korea, which imports many of its raw materials from the country; S Korea’s MFDS has instructed local companies to increase production of paracetamol 650mg tablets until April 2023 to address the issue of shortages as domestic Covid-related demand has also been high
  • Panic-buying of paracetamol-based products also ensued in Hong Kong; according to The Epoch Times, Lam Wai-man, Chairperson of the HK General Chamber of Pharmacy, said sales of Haleon’s Panadol had risen by 30-40% in a week and he believed that many of the products were being sent to Mainland China
Panadol is out of stock in many HK retail outlets. Source: The Epoch Times

  • The South China Morning Post reports that stocks of almost all TCM marketers rose (according to East Money) following the easing of restrictions, supported by the National Health Commission’s releasing a new list of 30+ TCMs recommended for treatment of mild Covid symptoms

Comment from CHC Insight Asia-Pacific Senior Editor, Nicola Allan: China has been pursuing a Zero Covid strategy for almost three years, which has adversely impacted the CHC market in Asia-Pacific in several ways. Systemic analgesics and cough & cold remedies in China have been affected by intermittent restrictions on their sale as the authorities sought to monitor people suffering from coronavirus symptoms such as cough and fever. In addition, China has historically outperformed the global CHC retail market, but in the 12 months to September 2022, growth of 3.6% was below the global average (+7%) as lockdowns pushed people to shop online. Meanwhile, countries such as Australia, Japan and HK have lost sales as a result of a lack of Chinese tourist shoppers. HK has been particularly hard hit, so the news that quarantine-free travel to / from the Mainland is set to resume as early as January 2023 will no doubt be welcome news to retailers around the border. There will likely be some bumps in the road regarding supply issues and the impact of Covid spreading through China, but hopefully the relaxed rules will have a positive effect on overall sales in the world’s No.2 CHC market.

We are pleased to announce that experts from J&J, Nielsen, McCann and other companies will join Nicholas on-stage at our 33rd European CHC Conference, taking place in London on 19-21 April 2023! See the latest agenda here. Stay tuned for further topics and speaker sessions to be announced! You can save with the early bird booking discount when you book your place. For more information, or for group booking discounts and sponsorship opportunities, please contact elizabeth.bernos@NicholasHall.com.

Global social media ad revenues stall

The winter update of the MAGNA (IPG Media Brands) Global Ad Forecast predicts that media owners’ advertising revenues will reach US$833bn in 2023, up 5% vs 2022. Despite challenging economic conditions, traditional media companies (TV, audio, publishing, out-of-home) saw ad revenues grow by 2.5% this year, while digital media companies grew by 9%. This is the narrowest growth gap ever observed by MAGNA, signalling that editorial media brands remain attractive and relevant as they now combine brand safety with cross-platform reach.

Multiple factors, including plateauing reach & usage and targeting limitations (as a result of Apple’s post-iOS 14 environment), combined to cause social media advertising to stall in 2022: global sales grew by just 4.4% to US$149bn, well down on the growth rates of 20-35% observed in the previous three years. TikTok is the only social media owner to post advertising growth, while incumbent social networks suffered flat or declining ad sales, especially in Europe and North America. MAGNA expects social media advertising to accelerate only slightly in 2023 (+6.8%).

Vincent Létang, EVP, Global Market Research at MAGNA and author of the report, said: “Advertising spending slowed down in the second half of 2022 because of economic uncertainty and issues affecting digital advertising formats, but traditional editorial media managed to grow by +2.5%. The gap in growth rates with digital advertising growth (+8.9%) was the narrowest ever measured by MAGNA, suggesting that the long-term transition to a digital-centric marketing landscape has slowed down following the Covid acceleration.

Nicholas Hall Writes: “What are the ideal channels of distribution and communication post-Covid, when consumers clearly are omnivorous and want the best of all possible worlds and flexibility in choosing brands and spending their hard-won cash in this global recession? It seems that there has never been a greater need for searching questions about the validity of brand strategies and marketing execution, which is needed both within companies and in media like CHC.Newsflash.

For more information on the news service, or to set up a trial of CHC.Newsflash or CHC.NewDirections to kickstart your 2023, contact melissa.lee@NicholasHall.com.

RETAIL CHC REMAINS BUOYANT IN MAT Q3 (+7.0%)

The MAT Q3 2022 update from DB6 shows the global retail market advanced by 7.0% in the 12 months to end-September 2022. Globally, this represents another strong single-digit result, albeit continuing to slow from record DB6 highs earlier in the year; with the exception of dermatologicals, all major categories observed a slowdown from MAT Q2 2022.

In terms of geographies, Europe (+10.7%) held its position as the fastest-growing region globally, with many key markets maintaining double-digit growth, driven by sustained significant increases in the cough, cold & allergy category (+28.9%), as well as continued robust growth in analgesics (+10.4%). Largest market Germany remained on a par with MAT Q2 2022 (+10.6%), with other Big 5 Western European markets similarly displaying solid advances, notably Spain (+15.1%). Poland was the strongest performing market (+17.9%), and for now, Russia’s growth remains healthy (+10.0%).

Americas (+7.5%) was the second-fastest growing region, although leading market USA saw its growth dip below the global average for the first time this year (+5.8%). Impressive MAT performances in cough, cold & allergy (+27.5%) offset more subdued returns in other segments, notably a flat VMS result and continued decline in dermatologicals (-3.0%). In Latin America, leading market Brazil improved over MAT Q2 2022 (+18.7%), with strong increases observed across most major categories: cough, cold & allergy (+55.1%), analgesics (+18.9%) and dermatologicals (+11.4%) were the most noteworthy.

CountryMAT Q3 2022 sales ($bn)22/21%
USA40.0+5.8
China32.0+3.6
Japan7.0+1.7
Germany5.5+10.6
France4.8+9.9
Brazil4.5+18.7
Italy4.5+11.2
India4.2+7.3
Russia4.1+10.0
UK3.2+11.9
GLOBAL CHC158.3+7.0

Asia (+4.3%) held on to its comparatively muted growth. Largest market China (+3.6%) returned low single-digit growth in view of continuing lockdown restrictions, as well as pharmacy sales restrictions on particular products, primarily impacting cough & cold categories and systemic analgesics. A continued positive increase for No.2 ranked Japan (+1.7%), aided by a dynamic systemic analgesic performance (+11.6%), helped to offset the slight slowing in China; combined, these markets have a share of almost 70% of total regional sales.

Nicholas Hall Writes: With the all-important Q3 market figures announced above by my colleague, Kayleigh Griffin-Hooper and her team, showing that industry sales are holding up well, we expect this to be something of a record year. I’m very much looking forward to seeing the complete 2022 data set next March, when we will be able to review the continued growth of e-Commerce, and then we’ll know whether the industry has kept up with or even exceeded the 6.1-6.5% growth rate experienced during the pandemic.

We are pleased to announce a special end-of-year Reports sale, offering up to 50% across many of our titles until 31 December. To find out more about other year-end discounts across our services, or to create your custom discounted reports package, please contact melissa.lee@NicholasHall.com.

Female-oriented A+P dominates Nicholas Hall’s APAC Awards

CHC Insight’s Senior Editor, Nicola Allan, summarises the Creative Marketing Award winners from last week’s Nicholas Hall’s APAC e-Conference:

  • Winner: Kalbe Consumer Health’s Mixagrip in Indonesia

The growth-driving campaign for Indonesia’s No.1 OTC systemic cold & flu remedy was centred around the idea that work and family pressures, climate issues and the pandemic make the “sandwich generation” tired and susceptible to illness but they cannot afford to miss a day of work. This led to the #AntiSkipHari (“No Skip Days”) initiative, which began with TV ads for Mixagrip and was expanded – in collaboration with creative company Ideacultura – with a digital video that recognises the pressure of daily responsibilities, plus offline marketing including posters on commuter trains and murals created by local artists. Kalbe’s goals were to help consumers avoid having to take time off work through illness, dispel the belief that cough & cold remedies cause drowsiness and fight back in a competitive category where rival brands focus only on TV and digital marketing

  • 2nd place: ZP Therapeutics campaign for Physiogel in the Philippines

In 2020, a year of reset and self-care owing to the onset of Covid-19, ZP Therapeutics revived Physiogel following a hiatus from the spotlight. A digital campaign shared the message that only Physiogel contains BioMimic Technology to strengthen sensitive skin and make it soft, which led to the concept of “Strength in Softness”, a celebration of the gentle strength that women possess. From this, the Physiogel sisterhood (SiS) emerged including Strong Skin Stories sessions on Facebook Live featuring influencers and skin care experts. In 2022, the campaign was expanded with the SiS Days Out programme, where women who donated empty skin care bottles to be recycled were given tickets to free Physiogel wellness & pampering events. These strategies led to consumer reach far exceeding expectations and an above-average brand engagement rate

  • 3rd place: Sanofi’s Ostelin in Australia

Australia’s dominant vitamin D brand was supported by “Ostelin Project Strong”, a campaign based on the idea that “Strong isn’t what a woman does. It’s who we are”. Sanofi partnered with visual media company Getty Images to showcase hundreds of photos of women that show a broad interpretation of women’s strength with the aim of enticing the younger generation and encouraging them to think about bone health without disenchanting the core 55+ target audience. Ostelin Project Strong, which boosted brand sales and share, also partnered with the 100 Women charity to support its mission of empowering women in various aspects of life

Nicholas Hall Writes: The Awards were of a very high standard and since we added the 5-minute case studies from companies showcasing their campaigns, the number and quality of entries have increased every year. We shortlisted four entries for online voting by delegates, not including the Special Award winner, Bayer China’s Canesten. The three campaigns shown above were worthy winners, but I’m going to give a special shout-out to a non-winner, Sanofi Korea’s Dulcolax for “K-Poop Star”. The case study showed a 360° campaign that attempts to break the taboo of constipation. Sadly we weren’t shown Dulcolax’s Tik Tok digital ads, which are some of the best I’ve ever seen, and absolutely in line with K-Pop culture as a way of reaching a younger target audience. Turning K-Pop into K-Poop is just brilliant.

Put your campaigns in the spotlight when you enter for our CHC Marketing Awards, to be presented during Nicholas Hall’s 33rd European CHC Conference in London on 19-21 April. For more information on entry criteria, or to book your place at this conference and save with the early bird booking discount, please contact elizabeth.bernos@NicholasHall.com.

Humanity hits milestone of global population of 8bn

The “Day of 8bn”, officially marked on 15th November 2022, is a milestone moment for humanity, according to the UN Population Fund, and “a testament to scientific breakthroughs and improvements in nutrition, public health and sanitation”, said UN Secretary-General António Guterres. However, it comes with worsening economic inequality and environmental damage. “Unless we bridge the yawning chasm between the global haves and have-nots, we are setting ourselves up for an 8bn-strong world filled with tensions and mistrust, crisis and conflict,” warned Guterres. Whether populations are growing or shrinking, every country must be equipped to provide good quality of life and lift up the most marginalised citizens. “We cannot rely on one-size-fits-all solutions in a world in which the median age is 41 in Europe, compared to 17 in sub-Saharan Africa,” noted UNFPA Chief, Natalia Kanem. “To succeed, all population policies must have reproductive rights at their core, invest in people and planet, and be based on solid data.” 

UN data indicates that the global fertility rate is now at 2.3 (down from 3.3 in 1990) and getting close to the “replacement rate” of 2.1, at which point the global population will stabilise (projected to be at some point between 2080 and 2100) and then decline. In the meantime, Africa is projected by the UN to drive half of the world’s population growth in the next 40 years, while India and Pakistan are projected to drive population growth in Asia.

Source: UN

Nicholas Hall Writes: So, as of last Tuesday there are 8bn of us on this tiny planet, a mixture of the comparatively wealthy and those who struggle; the enlightened and those who suffer from dictators with a big stick and a stone age mentality; and those who want to be more healthy. Eleven years ago, there were 7bn of us, and some experts are taking comfort from the fact that it will take 15 years before we become 9bn. And apparently our population will peak at 10.4bn sometime in the 2080s, always assuming that Dr Strangelove in Moscow doesn’t push the red button.

Actually, the topic of better health is one of the few with which we are almost all agreed, but it is a decades-old story of more people chasing increasingly-scarcer resources. Despite the amazing breakthroughs in new ways of treating serious diseases, self-care still has the potential to deliver more benefits to more people than any other component of the global healthcare system. Self-care is more than just OTC, of course, and improved lifestyle has a massive role to play if we can encourage more exercise, better diet and a cleaner environment. But our pills in bottles, tablets in strips, creams in tubes have so much more to offer in terms of raising standards of public health – if we can only get the message across.

Explore the factors impacting CHC across Asia during our Asia-Pacific e-Conference, taking place online this week! The event will also include the presentation of our Regional CHC Creative Marketing Award. There is still time to confirm your participation – for more information, or to register, please contact elizabeth.bernos@NicholasHall.com without delay.

Focus on China: MNCs reveal CHC launch plans at CIIE

Leading global CHC marketers revealed their latest launch plans and deals at the 5th China International Import Expo (CIIE), held in Shanghai last week:

  • Sanofi renewed its strategic co-operation agreement with China Resources Sanjiu, with whom it has worked since 2016, with a focus on the marketing of Essentiale. The parties will deepen co-operation and expand in the field of liver health, starting with the launch of Yi Shan Li, a sister product to Essentiale positioned to meet daily liver health needs. Sanofi also plans to launch Allegra allergy remedy in China and, via its Australian brand Ostelin, the company recently signed a strategic co-operation agreement with cross-border business solutions platform Huatang Dachang to bring better bone health options to Chinese consumers
  • Bayer diversified vitamin C brand Redoxon with the launch of Calcium, Vitamin D & Vitamin C chewable tablets for adults and gummies for children to support bone health. These line extensions, which are a result of an existing strategic co-operation with Xianle Health (Sirio Pharma), are part of a strategy to build the brand into a comprehensive nutrition range (Redoxon probiotic powder was launched in China in 2021). As part of its co-operation with Jiangnan University, Bayer is developing a Scientific Innovation Laboratory of Probiotics, which will explore the benefits of probiotics beyond intestinal health to include categories such as allergy and immunity. The company also renewed its long-standing co-operation agreement with Shandong Xianhua Pharmaceutical to expand collaboration beyond nutritional categories to cover digestive tract health, pain and dry cough. Finally, Bayer, which markets ketoconazole-based scalp care brand Kang Wang, signed a co-operation agreement with Colori Cosmetics to jointly develop daily scalp care products
Source: SHINE
  • Haleon marked its CIIE debut with the news that it will soon launch Voltaren patches (diclofenac sodium) in China, joining the established gel version. It also showcased recently-launched products including Centrum Multivitamin & Zinc Gummy and Caltrate Milk Minerals Gummy Strawberry Yoghurt flavour. In addition, the marketer highlighted digital self-assessment tools such as the Caltrate Magic Mirror Mobility test and Voltaren Smart Posture test
  • J&J China Self-Care showcased products from around the world at the CIIE, such as children’s Tylenol and Benylin products, in line with China’s focus on children’s health and encouragement of personal health management. Recognising the need for improved understanding of self-care, J&J supported the China Health Promotion Foundation in launching a self-care promotion programme and has been working with academic associations and medical institutions to develop strategies to boost the concept of self-care in China

Nicholas Hall Writes: There is still a good appetite for investing in the Chinese CHC market by the leading players in our industry. Innovative new products continue to be launched there. Other emerging markets are interested in promoting trade. And, intriguingly, our most acquisitive player, Nestlé Health Science, wants to increase its China footprint – I’m sure that is one of the reasons why the company is looking at Blackmores, assuming that the rumours are true.

There’s still time to register for our upcoming Asia-Pacific e-Conference on 23 November! With presentations from Nicholas Hall and leading marketers, this online event also includes the presentation of our APAC Creative Marketing Awards. For more information, or to register without delay, please contact elizabeth.bernos@NicholasHall.com.